315188-30-8

Basic information

• Product Name: 2-Amino-5-bromo-4-fluoro-benzaldehyde
• Synonyms: 2-Amino-5-bromo-4-fluoro-benzaldehyde
• CAS NO: 315188-30-8
• Molecular Formula: C₇H₅BrFNO
• Molecular Weight: 218.0231032
• Mol File: 315188-30-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 297.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.761±0.06 g/cm3(Predicted)
• PKA: -1.25±0.13(Predicted)
• CAS DataBase Reference: 2-Amino-5-bromo-4-fluoro-benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-bromo-4-fluoro-benzaldehyde(315188-30-8)
• EPA Substance Registry System: 2-Amino-5-bromo-4-fluoro-benzaldehyde(315188-30-8)

Safety Data

• Hazardous Substances Data: 315188-30-8(Hazardous Substances Data)

Usage

Physical State

Yellow solid

Solubility

Soluble in organic solvents

Functional Groups

Benzene ring with an aldehyde ( \textC=O ) functional group
Amino ( \textNH2 ) group
Bromo ( \textBr ) group
Fluoro ( \textF ) group

Utility

Used in the synthesis of pharmaceuticals and agrochemicals

Derivative

Benzaldehyde derivative

Reactivity

The presence of amino, bromo, and fluoro groups enhances its reactivity, making it useful for various chemical reactions

Applications

Valuable in medicinal and agricultural applications as a building block for more complex molecules

Upstream product

• 213382-45-7 5-bromo-4-fluoro-2-nitro-benzaldehyde 
• 77771-02-9 3-bromo-4-fluorobenzaldehyde 

Downstream Products

• 1319194-61-0 (2-(2-amino-7-fluoro-3-morpholinoquinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 
• 315188-29-5 5-Bromo-4-fluoro-2-iodobenzaldehyde 

Relevant articles and documents

QUINAZOLINYL COMPOUNDS AND METHODS OF USE

Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.

AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B1, B2, B3, L, R1, R2, ring Z, m and n of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).